Pulse Biosciences Inc
PLSE14.400USD
-0.460-3.10%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
975.43MMarket Cap
LossP/E TTM
More Details of Pulse Biosciences Inc Company
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
Pulse Biosciences Inc Info
Ticker SymbolPLSE
Company namePulse Biosciences Inc
IPO dateMay 18, 2016
CEOLaviolette (Paul A)
Number of employees75
Security typeOrdinary Share
Fiscal year-endMay 18
Address3957 Point Eden Way
CityHAYWARD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94545
Phone15109064600
Websitehttps://www.pulsebiosciences.com/
Ticker SymbolPLSE
IPO dateMay 18, 2016
CEOLaviolette (Paul A)
Company Executives of Pulse Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
48.79M
+0.32%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
Independent Director
Independent Director
873.47K
--
Mr. Darrin R. Uecker
Mr. Darrin R. Uecker
Chief Technology Officer, Director
Chief Technology Officer, Director
284.62K
+0.07%
Mr. Jon Skinner
Mr. Jon Skinner
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
778.00
--
Mr. Kevin P. Danahy
Mr. Kevin P. Danahy
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Mitchell E. Levinson
Mr. Mitchell E. Levinson
Chief Strategy Officer
Chief Strategy Officer
--
--
Mr. Paul A. Laviolette
Mr. Paul A. Laviolette
Co-Chairman of the Board, President, Chief Executive Officer
Co-Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Lead Independent Director
Lead Independent Director
--
--
Mr. Richard A. (Rich) van Den Broek
Mr. Richard A. (Rich) van Den Broek
Independent Director
Independent Director
--
--
Mr. Steven T. Weber
Mr. Steven T. Weber
Vice President of Accounting and Global Corporate Controller, Principal Accounting Officer
Vice President of Accounting and Global Corporate Controller, Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
48.79M
+0.32%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
Independent Director
Independent Director
873.47K
--
Mr. Darrin R. Uecker
Mr. Darrin R. Uecker
Chief Technology Officer, Director
Chief Technology Officer, Director
284.62K
+0.07%
Mr. Jon Skinner
Mr. Jon Skinner
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
778.00
--
Mr. Kevin P. Danahy
Mr. Kevin P. Danahy
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Mitchell E. Levinson
Mr. Mitchell E. Levinson
Chief Strategy Officer
Chief Strategy Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Systems
0.00
0.00%
Cycle units
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
North America
0.00
0.00%
Rest of World
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Systems
0.00
0.00%
Cycle units
0.00
0.00%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Duggan (Robert William)
72.00%
BlackRock Institutional Trust Company, N.A.
1.72%
The Vanguard Group, Inc.
1.64%
Zanganeh (Mahkam)
1.29%
BofA Global Research (US)
1.19%
Other
22.17%
Shareholders
Shareholders
Proportion
Duggan (Robert William)
72.00%
BlackRock Institutional Trust Company, N.A.
1.72%
The Vanguard Group, Inc.
1.64%
Zanganeh (Mahkam)
1.29%
BofA Global Research (US)
1.19%
Other
22.17%
Shareholder Types
Shareholders
Proportion
Individual Investor
73.94%
Investment Advisor
4.80%
Investment Advisor/Hedge Fund
2.45%
Research Firm
1.30%
Hedge Fund
0.16%
Pension Fund
0.09%
Bank and Trust
0.09%
Sovereign Wealth Fund
0.03%
Other
17.13%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
176
6.04M
8.91%
-573.55K
2025Q2
170
55.62M
82.69%
-443.29K
2025Q1
171
55.60M
82.67%
-380.27K
2024Q4
161
55.79M
90.70%
+5.71M
2024Q3
153
49.96M
81.56%
+5.91M
2024Q2
136
43.75M
79.18%
-238.05K
2024Q1
135
43.68M
79.09%
-52.16K
2023Q4
133
43.32M
78.65%
+197.90K
2023Q3
133
41.46M
75.60%
-827.09K
2023Q2
134
41.10M
75.12%
+5.77M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Duggan (Robert William)
48.63M
72.27%
+34.66K
+0.07%
Sep 10, 2025
BlackRock Institutional Trust Company, N.A.
1.19M
1.78%
-19.88K
-1.64%
Jun 30, 2025
The Vanguard Group, Inc.
1.22M
1.81%
+380.69K
+45.37%
Jun 30, 2025
Zanganeh (Mahkam)
873.47K
1.3%
--
--
Aug 25, 2025
BofA Global Research (US)
783.54K
1.16%
+5.78K
+0.74%
Jun 30, 2025
Geode Capital Management, L.L.C.
499.46K
0.74%
+33.74K
+7.25%
Jun 30, 2025
State Street Investment Management (US)
419.26K
0.62%
+12.00
+0.00%
Jun 30, 2025
Uecker (Darrin R)
284.41K
0.42%
+161.53K
+131.47%
Sep 17, 2025
Griffin Asset Management, Inc.
229.66K
0.34%
-3.90K
-1.67%
Jun 30, 2025
Northern Trust Investments, Inc.
192.85K
0.29%
-7.22K
-3.61%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Inspire Small/Mid Cap ESG ETF
0.16%
iShares Micro-Cap ETF
0.06%
iShares Russell 2000 Growth ETF
0.02%
ProShares UltraPro Russell2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
Fidelity MSCI Health Care Index ETF
0.01%
View more
Inspire Small/Mid Cap ESG ETF
Proportion0.16%
iShares Micro-Cap ETF
Proportion0.06%
iShares Russell 2000 Growth ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Fidelity MSCI Health Care Index ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Pulse Biosciences Inc?
The top five shareholders of Pulse Biosciences Inc are:
Duggan (Robert William) holds 48.63M shares, accounting for 72.27% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.19M shares, accounting for 1.78% of the total shares.
The Vanguard Group, Inc. holds 1.22M shares, accounting for 1.81% of the total shares.
Zanganeh (Mahkam) holds 873.47K shares, accounting for 1.30% of the total shares.
BofA Global Research (US) holds 783.54K shares, accounting for 1.16% of the total shares.
Duggan (Robert William) holds 48.63M shares, accounting for 72.27% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.19M shares, accounting for 1.78% of the total shares.
The Vanguard Group, Inc. holds 1.22M shares, accounting for 1.81% of the total shares.
Zanganeh (Mahkam) holds 873.47K shares, accounting for 1.30% of the total shares.
BofA Global Research (US) holds 783.54K shares, accounting for 1.16% of the total shares.
What are the top three shareholder types of Pulse Biosciences Inc?
The top three shareholder types of Pulse Biosciences Inc are:
Duggan (Robert William)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Duggan (Robert William)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
How many institutions hold shares of Pulse Biosciences Inc (PLSE)?
As of 2025Q3, 176 institutions hold shares of Pulse Biosciences Inc, with a combined market value of approximately 6.04M, accounting for 8.91% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -73.79%.
What is the biggest source of revenue for Pulse Biosciences Inc?
In FY2023, the Systems business generated the highest revenue for Pulse Biosciences Inc, amounting to -- and accounting for --% of total revenue.
